INT2606

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1979
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 10
Total Number 10
Disease Relevance 4.60
Pain Relevance 1.82

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (NEU1) hydrolase activity, acting on glycosyl bonds (NEU1) cytoplasmic membrane-bounded vesicle (NEU1)
plasma membrane (NEU1) lysosome (NEU1)
Anatomy Link Frequency
PMNs 5
lymphocytes 1
NEU1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 57 97.48 Very High Very High Very High
cytokine 24 96.96 Very High Very High Very High
Inflammatory response 1 96.12 Very High Very High Very High
aspirin 6 94.38 High High
cINOD 6 93.48 High High
Pain 2 92.60 High High
Arthritis 1 80.52 Quite High
Analgesic 1 78.48 Quite High
rheumatoid arthritis 1 75.52 Quite High
Osteoarthritis 1 73.76 Quite High
Disease Link Frequency Relevance Heat
Acne 164 99.98 Very High Very High Very High
INFLAMMATION 64 98.58 Very High Very High Very High
Agranulocytosis 2 98.28 Very High Very High Very High
Infection 16 97.56 Very High Very High Very High
Neutropenia 4 96.04 Very High Very High Very High
Increased Venous Pressure Under Development 1 93.16 High High
Pain 2 92.60 High High
Hyperplasia 1 88.96 High High
Necrosis 3 84.76 Quite High
Cancer 5 84.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In vitro, piroxicam inhibits both superoxide anion production and lysosomal enzyme release from human neutrophils and also inhibits IgM-rheumatoid factor production by human lymphocytes.
Localization (release) of lysosomal enzyme in lymphocytes
1) Confidence 0.41 Published 1983 Journal Eur J Rheumatol Inflamm Section Abstract Doc Link 6345166 Disease Relevance 0.71 Pain Relevance 0.30
The sebocytes treated with sialidase or GFP were then co-cultured with P. acnes [multiplicity of infection (MOI) 1?
Localization (treated) of sialidase associated with acne and infection
2) Confidence 0.29 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2212713 Disease Relevance 0.90 Pain Relevance 0.06
These results suggest that a vaccine targeting sialidase effectively suppresses P. acnes-induced production of the pro-inflammatory cytokine MIP-2 in the mice.


Localization (targeting) of sialidase associated with inflammation and cytokine
3) Confidence 0.25 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2212713 Disease Relevance 1.07 Pain Relevance 0.44
In contrast, the non-steroidal anti-inflammatory drugs (indomethacin, meclofenamic acid and aspirin), which only block the cyclo-oxygenase pathway of AA metabolism, had little effect on enzyme release from PMNs induced by the same stimuli. 5,8,11-Eicosatriynoic acid (ETI), a selective inhibitor of the lipoxygenase pathway of AA metabolism, caused a dose-dependent inhibition of lysosomal enzyme release elicited by Zx, f-met peptide, and A23187. p-Bromophenacyl bromide (BPB), which inhibits the phospholipase A2 (PLA2) activity in several tissues, was found to cause a dose-dependent inhibition of lysosomal enzyme release induced by the same immunological and non-immunological stimuli.
Localization (release) of lysosomal enzyme in PMNs associated with aspirin, inflammation and cinod
4) Confidence 0.18 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.09 Pain Relevance 0.13
We have studied the role of arachidonic acid (AA) metabolism in the release of lysosomal enzymes (beta-glucuronidase and lysozyme) from human polymorphonuclear leukocytes (PMNs). 5,8,11,14-Eicosatetraenoic acid (ETYA), which inhibits both the cyclo-oxygenase and the lipoxygenase pathways of AA metabolism, was found to cause a dose-dependent inhibition of lysosomal enzyme release from human PMNs induced by immunological (i.e., serum-treated zymosan: Zx) and nonimmunological stimuli (i.e., formyl methionine-containing peptide and the Ca2+ ionophore A23187).
Localization (release) of lysosomal enzyme in PMNs
5) Confidence 0.18 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.08 Pain Relevance 0.12
In contrast, the non-steroidal anti-inflammatory drugs (indomethacin, meclofenamic acid and aspirin), which only block the cyclo-oxygenase pathway of AA metabolism, had little effect on enzyme release from PMNs induced by the same stimuli. 5,8,11-Eicosatriynoic acid (ETI), a selective inhibitor of the lipoxygenase pathway of AA metabolism, caused a dose-dependent inhibition of lysosomal enzyme release elicited by Zx, f-met peptide, and A23187. p-Bromophenacyl bromide (BPB), which inhibits the phospholipase A2 (PLA2) activity in several tissues, was found to cause a dose-dependent inhibition of lysosomal enzyme release induced by the same immunological and non-immunological stimuli.
Localization (release) of lysosomal enzyme in PMNs associated with aspirin, inflammation and cinod
6) Confidence 0.18 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.09 Pain Relevance 0.14
Possible role of arachidonic acid and of phospholipase A2 in the control of lysosomal enzyme release from human polymorphonuclear leukocytes.
Localization (release) of lysosomal enzyme in polymorphonuclear leukocytes
7) Confidence 0.16 Published 1983 Journal J Clin Lab Immunol Section Title Doc Link 6644791 Disease Relevance 0.07 Pain Relevance 0.11
It is concluded that P and S exert their antiinflammatory action at least in part by interfering with PMN hyperadhesiveness and lysosomal enzyme release.
Localization (release) of lysosomal enzyme associated with inflammation
8) Confidence 0.03 Published 1979 Journal Schweiz Med Wochenschr Section Abstract Doc Link 482916 Disease Relevance 0.40 Pain Relevance 0.08
P and S also abrogated adherence-induced lysosomal enzyme release and FP-stimulated hexose monophosphate pathway (HMP) activity.
Localization (release) of lysosomal enzyme
9) Confidence 0.02 Published 1979 Journal Schweiz Med Wochenschr Section Abstract Doc Link 482916 Disease Relevance 0.53 Pain Relevance 0.18
In neutrophils, PGE2 can prevent chemotaxis, aggregation, superoxide production, lysosomal enzyme release and generation of leukotriene B4 [4], [10]–[14].
Localization (release) of lysosomal enzyme in neutrophils
10) Confidence 0.01 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2373884 Disease Relevance 0.66 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox